People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
“Ketamine is a safe medication when used under appropriate professional supervision, so FDA approval will lead to a safer, more well-regulated control and use of this medication in clinical ...
An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...